Asset Details
Do you wish to reserve the book?
IMMUNOHISTOCHEMICAL EXPRESSION OF P16 IN LOW GRADE UROTHELIAL CARCINOMA
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
IMMUNOHISTOCHEMICAL EXPRESSION OF P16 IN LOW GRADE UROTHELIAL CARCINOMA
Do you wish to request the book?
IMMUNOHISTOCHEMICAL EXPRESSION OF P16 IN LOW GRADE UROTHELIAL CARCINOMA
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
IMMUNOHISTOCHEMICAL EXPRESSION OF P16 IN LOW GRADE UROTHELIAL CARCINOMA
2021
Overview
Objective: To determine the frequency of Immunohistochemical expression of P16 in low grade urothelial carcinoma patients. Study Design: Cross sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from May 2018 to Jul 2019. Methodology: A total of 120 formalin-fixed and paraffin embedded blocks from patients having low grade urothelial carcinomawere included in the study and were stainedimmunohistochemically with P16 antibody. Expression of P16 was noted by two independent pathologists and nuclear stain of strong intensity was taken as positive. Results: There were 91 (76%) males and 29 (24%) females with age range from 18-85 years (mean 67.19 ± 11.5 years) female to male ratio was 1:3. P16 stain was positive in (70.8%) and negative in 37 (31%) of low gradeurothelial carcinoma cases. Conclusion: The p-16 is expressed in a significant number of urothelial carcinomas (low grade) and this marker could be used in routine practice for early identification of patients at high risk of progression to advanced stage.
